directed-evolution
(6)
Tina Boville wanted dragons. She built a bigger chemical alphabet.
Childhood science fiction gave Christina "Tina" Boville an idea: biology could make things nature had never tried. A detour through recycling bins, evolved enzymes and startup auctions turned that idea into Aralez Bio.
Tina Boville
Tina Boville is the co-founder and CEO of Aralez Bio, a Berkeley-based biotechnology company using directed evolution to make noncanonical amino acids - the building blocks behind a growing share of modern medicines. A biochemist trained at the University of Colorado and Caltech, where she worked in Nobel laureate Frances Arnold's lab, Boville turned an engineered enzyme platform into a company that can produce over 100 amino acids in single-step reactions, cutting manufacturing waste by up to 99%. She has been named to MIT Technology Review's Innovators Under 35, is an Activate Fellow, and in 2024 raised a $12 million Series A to scale production to tons per year.
Aralez Bio
Aralez Bio is a Berkeley, California biotechnology company that uses engineered enzymes and directed evolution to manufacture noncanonical amino acids (ncAAs) - the specialized building blocks used in peptide drugs and other pharmaceuticals. Spun out of Nobel Laureate Frances Arnold's Caltech lab in 2019, the company runs biocatalytic reactions that produce enantiopure ncAAs in a single step with water as the main byproduct, expanding the amino acid toolbox roughly 1,000-fold. Aralez sells a catalog of thousands of exclusive amino acids and offers custom synthesis and ton-scale production for pharmaceutical customers, including partners among the world's largest drug companies.
Noah Helman
Noah Helman is the co-founder and CEO of Industrial Microbes (iMicrobes), an Alameda, California synthetic biology company that engineers the central metabolism of microbes so they can eat cheap, renewable feedstocks - ethanol and methane - and spit out the chemicals normally pumped from petroleum. A Stanford applied-physics PhD who spent roughly a decade in physics labs before crossing into biology, Helman co-founded the company in 2014 with two fellow alumni of the biofuels startup LS9. iMicrobes targets drop-in, cost-competitive, net-zero versions of acrylic acid (for paints and adhesives) and acrylonitrile (for carbon fiber). The company went through Y Combinator's W15 batch, holds more than 20 patents, raised a $10M+ seed round in late 2024, and in 2025 announced it had scaled production of 100% bio-based, high-purity acrylic acid.
Triplebar
Triplebar is an Emeryville, California biotech company that pairs a high-throughput microfluidic screening platform with AI genomic models to run evolution at hyper-speed. By packing tens of millions of picoliter microreactors onto a palm-sized chip and testing thousands per second, it generates matched genotype-phenotype datasets that let partners optimize cell lines and microbial strains far faster and cheaper than conventional lab work. The platform powers products across food (precision fermentation, cultivated meat) and biopharma (biologics, cell-engaging cancer therapies).
Simcha Therapeutics
Simcha Therapeutics is a clinical-stage biopharmaceutical company in New Haven, Connecticut that uses directed evolution to engineer next-generation cytokine immunotherapies for cancer. Its lead program, ST-067, is a first-in-class 'decoy-resistant' interleukin-18 (IL-18) variant engineered to evade the natural decoy protein (IL-18BP) that tumors exploit to silence the immune system. Spun out of Aaron Ring's lab at Yale School of Medicine and backed by $40M in Series B financing, Simcha is advancing ST-067 through Phase 1/2 trials in solid tumors and partnering with Janssen to armor CAR T cell therapies.